A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies
Status:
Completed
Trial end date:
2020-11-26
Target enrollment:
Participant gender:
Summary
A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety, Tolerability,
Pharmacokinetics, and Anti-tumor Activity of Durvalumab (MEDI4736) in combination with
tremelimumab in Chinese Patients with Advanced Malignancies